Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Analyst Ratings Changes

Several equities analysts have commented on RCKT shares. William Blair reissued an "outperform" rating on shares of Rocket Pharmaceuticals in a report on Thursday, May 5th. SVB Leerink decreased their target price on shares of Rocket Pharmaceuticals from $66.00 to $64.00 and set an "outperform" rating on the stock in a report on Wednesday, July 6th. Needham & Company LLC decreased their target price on shares of Rocket Pharmaceuticals from $75.00 to $62.00 and set a "buy" rating on the stock in a report on Tuesday, May 17th. Chardan Capital raised their price target on shares of Rocket Pharmaceuticals from $60.00 to $62.00 and gave the company a "buy" rating in a research note on Thursday, May 19th. Finally, Stifel Nicolaus raised their price target on shares of Rocket Pharmaceuticals from $63.00 to $67.00 in a research note on Thursday, May 19th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, Rocket Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.80.

Rocket Pharmaceuticals Price Performance

Shares of RCKT traded up $0.68 during mid-day trading on Wednesday, reaching $16.91. The company had a trading volume of 541,555 shares, compared to its average volume of 677,417. The company's 50 day simple moving average is $14.29 and its 200 day simple moving average is $14.33. Rocket Pharmaceuticals has a 1-year low of $7.57 and a 1-year high of $37.44. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.68 and a current ratio of 15.68. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -6.26 and a beta of 1.68.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Rating) last posted its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.16). During the same quarter in the prior year, the business posted ($0.55) EPS. Analysts expect that Rocket Pharmaceuticals will post -2.72 EPS for the current year.